Z Gastroenterol 2013; 51(3): 301-305
Georg Thieme Verlag KG Stuttgart · New York
Gemeinsame Stellungnahme der DGVS, der Deutschen Leberhilfe, der Deutschen Leberstiftung und eines Facharztes für Allgemeinmedizin zur Aufnahme des ALT-Wertes in den Check-up 35 plus im Rahmen des Präventionsförderungsgesetzes
Literatur
1 EASL-EORTC Clinical Practice Guidelines. Management of hepatocellular carcinoma. Journal of Hepatology 2012; 56: 908-943
2 McGlynn KA, London WT. The global epidemiology of hepatocellular carcinoma: present and future. Clin Liver Dis 2011; 15 (2) 223-243 vii-x
3 Wedemeyer H et al. ALT als Screeningparameter für Lebererkrankungen: eine kritische Evaluation der Evidenz. Z Gastroenterol 2010; 48: 46-55
4 Kim HCNC, Jee SH, Han KH et al. Normal serum aminotransferase concentration and risk of mortality from liver diseases: prospective cohort study. BMJ 2004; 328 (7446) 983
5 Wiegand J, Bätz O, Wolffram I, Kramer J, Jedrysiak K, Tenckhoff H, Berg T. Identification of patients with HBV and HCV infection in the primary care setting: Pre-defined risk scenarios are a better screening strategy than elevated ALT values. Z Gastroenterol 2013; 51: P_5_78
6 Baumeister SEVH, Marschall P et al. Impact of fatty liver disease on health care utilization and costs in a general population: a 5-year observation. Gastroenterology 2008; 134: 85-94
7 Vermehren J, Schlosser B, Domke D et al. High prevalence of anti-HCV antibodies in two metropolitan emergency departments in Germany: a prospective screening analysis of 28,809 patients. PLOS one 2012; 7: e41206
8 Cornberg M, Protzer U, Petersen J et al. Aktualisierung der S3-Leitlinie zur Prophylaxe, Diagnostik und Therapie der Hepatitis-B-Virusinfektion. AWMF-Register-Nr.: 021/011. Z Gastroenterol 2011; 49: 871-930
9 van der Meer AJ, Veldt BJ, Feld JJ et al. Association between sustained virological response and all-cause mortality among patients with chronic hepatitis C and advanced hepatic fibrosis. JAMA 2012; 308 (24) 2584-2593
10 Toy M et al. Potential impact of long-term nucleoside therapy on the mortality and morbidity of active chronic hepatitis B. Hepatology 2009; 50 (3) 743-751
11 Buti M et al. Modeling the cost-effectiveness of different oral antiviral therapies in patients with chronic hepatitis B. J Hepatol 2009; 51 (4) 640-646
12 Aidelsburger P et al. German Hepatitis C Economic Database – Methodological Approach and Data Assessment. 9th Biennial meeting of the European Society of Medical Decision Making, June 6–8, 2004, Rotterdam, The Netherlands, S. 76
13 Aidelsburger P et al. Struktur und Inhalt der German Hepatitis C Economic Database. Inform Biom Epidemiol Med Biol 2003; 34 (3) 449
14 Buggisch P, Petersen J, Urlea-Schön I et al. High prevalence of chronic hepatitis C in 8009 patients with migration background living in Germany. AASLD 2012 in Boston. Hepatology 2012; 56: A768
15 Tozun N, Ozdogan OC, Cakaloglu Y et al. Nationwide prevalence study and risk factors for hepatitis A, B, C and D infections in Turkey. Hepatology 2010; 52: 697A
16 Hatzakis A, Wait S, Bruix J et al. The state of hepatitis B and C in Europe: report from the hepatitis B and C summit conference. J Viral Hepatitis 2011; 18: 1-16
17 Balabanova Y, Gilsdorf A, Buda S et al. Communicable diseases prioritized for surveillance and epidemiological research: results of a standardized prioritization procedure in Germany 2011. PLoS ONE 2011; 6: e25691
18 Chalasani N, Younossi Z, Lavine JE, Diehl AM, Brunt EM, Cusi K, Charlton M, Sanyal AJ. The Diagnosis and Management of Non-Alcoholic Fatty Liver Disease: Practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association. Hepatology 2012; 55 (6)
19 European Association for the Study of the Liver. EASL Clinical Practical Guidelines: Management of Alcoholic Liver Disease. Journal of Hepatology 2012; 57: 399-420
20 Meier Y et al. Incidence of drug-induced liver injury in medical inpatients. Eur J Clin Pharmacol 2005; 61: 135-143
21 Andrade RJ et al. Drug-induced liver injury: an analysis of 461 incidences submitted to the Spanish registry over a 10-year period. Gastroenterology 2005; 129: 512-521
22 Manns MP, Czaja AJ, Gorham JD et al. AASLD PRACTICE GUIDELINES: Diagnosis and Management of Autoimmune Hepatitis. Hepatology 2010; 51 (6)
23 Goessling WMJ, Vasan RS et al. Aminotransferase levels and 20-year risk of metabolic syndrome, diabetes, and cardiovascular disease. Gastroenterology 2008; 135: 1935-1944
24 Schindhelm RK, Dekker JM, Nijpels G et al. Alanine aminotransferase predicts coronary heart disease events: a 10-year follow-up of the Hoorn Study. Atherosclerosis 2007; 191 (2) 391-396 [Epub 2006 May 8]
